Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Pulmonx ( (LUNG) ) is now available.
On March 2, 2026, Pulmonx Corporation entered into a new senior secured term loan facility of up to $60 million with Perceptive Credit Holdings V, LP, drawing an initial $40 million and gaining access to two additional $10 million tranches contingent on meeting specified revenue thresholds through 2027. The loan, maturing March 2, 2031, carries a floating interest rate with optional paid-in-kind interest for 36 months, is secured by substantially all company and key subsidiary assets, and requires Pulmonx to maintain minimum liquidity and revenue levels, with default provisions that could accelerate repayment.
As part of the financing, Pulmonx issued Perceptive a warrant on March 2, 2026 to purchase up to 1,000,000 common shares at a 25% premium to the recent 10-day volume-weighted average price and will issue additional warrants tied to any future delayed-draw borrowings under similar terms. Also on March 2, 2026, the company fully repaid and terminated its prior credit facility with Canadian Imperial Bank of Commerce without incurring early termination penalties, effectively refinancing its debt structure and adding equity-linked incentives for its new lender.
The most recent analyst rating on (LUNG) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Pulmonx stock, see the LUNG Stock Forecast page.
Spark’s Take on LUNG Stock
According to Spark, TipRanks’ AI Analyst, LUNG is a Neutral.
The score is primarily held down by weak financial health (persistent losses, rising leverage, and negative operating cash flow) and a bearish technical setup (below major moving averages with negative MACD). Valuation provides limited support due to losses and no dividend, while the earnings call was mixed with stable margin guidance and international growth but soft U.S. growth and declining cash.
To see Spark’s full report on LUNG stock, click here.
More about Pulmonx
Pulmonx Corporation operates in the medical technology sector, developing minimally invasive devices for the treatment of severe lung diseases. The company focuses on interventional pulmonology solutions, targeting patients with advanced emphysema and other chronic respiratory conditions in global healthcare markets.
Average Trading Volume: 520,762
Technical Sentiment Signal: Sell
Current Market Cap: $59.4M
For detailed information about LUNG stock, go to TipRanks’ Stock Analysis page.